Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 32.51 Billion KRW | 31.4% |
| 2022 | 24.74 Billion KRW | 2.34% |
| 2021 | 24.17 Billion KRW | 0.39% |
| 2020 | 24.08 Billion KRW | 7.45% |
| 2019 | 22.41 Billion KRW | -6.13% |
| 2018 | 23.87 Billion KRW | 45.01% |
| 2017 | 16.46 Billion KRW | 45.23% |
| 2016 | 11.33 Billion KRW | -21.67% |
| 2015 | 14.47 Billion KRW | -6.61% |
| 2014 | 15.49 Billion KRW | -0.86% |
| 2013 | 15.63 Billion KRW | -10.83% |
| 2012 | 17.53 Billion KRW | -26.13% |
| 2011 | 23.73 Billion KRW | 6.65% |
| 2010 | 22.25 Billion KRW | 31.88% |
| 2009 | 16.87 Billion KRW | -18.82% |
| 2008 | 20.79 Billion KRW | 21.28% |
| 2007 | 17.14 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 31.18 Billion KRW | 10.23% |
| 2024 Q1 | 28.28 Billion KRW | -12.98% |
| 2023 FY | 32.51 Billion KRW | 31.4% |
| 2023 Q1 | 23.19 Billion KRW | -6.24% |
| 2023 Q4 | 32.51 Billion KRW | 3.01% |
| 2023 Q3 | 31.56 Billion KRW | -7.55% |
| 2023 Q2 | 34.14 Billion KRW | 47.18% |
| 2022 Q2 | 23.25 Billion KRW | 7.87% |
| 2022 Q4 | 24.74 Billion KRW | 0.43% |
| 2022 Q3 | 24.63 Billion KRW | 5.96% |
| 2022 Q1 | 21.55 Billion KRW | -10.85% |
| 2022 FY | 24.74 Billion KRW | 2.34% |
| 2021 Q3 | 23.43 Billion KRW | 2.34% |
| 2021 FY | 24.17 Billion KRW | 0.39% |
| 2021 Q4 | 24.17 Billion KRW | 3.19% |
| 2021 Q1 | 23 Billion KRW | -4.47% |
| 2021 Q2 | 22.89 Billion KRW | -0.49% |
| 2020 Q4 | 24.08 Billion KRW | 12.79% |
| 2020 Q1 | 20.73 Billion KRW | -7.5% |
| 2020 Q2 | 20.95 Billion KRW | 1.05% |
| 2020 Q3 | 21.35 Billion KRW | 1.92% |
| 2020 FY | 24.08 Billion KRW | 7.45% |
| 2019 FY | 22.41 Billion KRW | -6.13% |
| 2019 Q4 | 22.41 Billion KRW | 5.04% |
| 2019 Q2 | 20.76 Billion KRW | 0.33% |
| 2019 Q1 | 20.69 Billion KRW | -13.33% |
| 2019 Q3 | 21.33 Billion KRW | 2.77% |
| 2018 Q3 | 20.55 Billion KRW | 13.48% |
| 2018 FY | 23.87 Billion KRW | 45.01% |
| 2018 Q1 | 17.11 Billion KRW | 3.95% |
| 2018 Q2 | 18.11 Billion KRW | 5.85% |
| 2018 Q4 | 23.87 Billion KRW | 16.14% |
| 2017 Q3 | 14.95 Billion KRW | 18.84% |
| 2017 FY | 16.46 Billion KRW | 45.23% |
| 2017 Q1 | 11.9 Billion KRW | 5.05% |
| 2017 Q4 | 16.46 Billion KRW | 10.07% |
| 2017 Q2 | 12.58 Billion KRW | 5.69% |
| 2016 FY | 11.33 Billion KRW | -21.67% |
| 2016 Q4 | 11.33 Billion KRW | 1.93% |
| 2016 Q3 | 11.12 Billion KRW | -2.67% |
| 2016 Q2 | 11.42 Billion KRW | -21.94% |
| 2016 Q1 | 14.64 Billion KRW | 1.15% |
| 2015 Q3 | 14.25 Billion KRW | 0.64% |
| 2015 Q1 | 14.99 Billion KRW | -3.24% |
| 2015 Q2 | 14.16 Billion KRW | -5.54% |
| 2015 FY | 14.47 Billion KRW | -6.61% |
| 2015 Q4 | 14.47 Billion KRW | 1.53% |
| 2014 Q2 | 12.73 Billion KRW | -5.14% |
| 2014 Q1 | 13.42 Billion KRW | -14.14% |
| 2014 FY | 15.49 Billion KRW | -0.86% |
| 2014 Q4 | 15.49 Billion KRW | 20.12% |
| 2014 Q3 | 12.9 Billion KRW | 1.32% |
| 2013 Q1 | 16.91 Billion KRW | -3.55% |
| 2013 FY | 15.63 Billion KRW | -10.83% |
| 2013 Q3 | 16.21 Billion KRW | -3.57% |
| 2013 Q2 | 16.81 Billion KRW | -0.55% |
| 2013 Q4 | 15.63 Billion KRW | -3.6% |
| 2012 Q4 | 17.53 Billion KRW | 0.0% |
| 2012 FY | 17.53 Billion KRW | -26.13% |
| 2012 Q1 | 18.52 Billion KRW | 0.0% |
| 2011 Q2 | 21.55 Billion KRW | 1.44% |
| 2011 Q3 | 23.07 Billion KRW | 7.03% |
| 2011 FY | 23.73 Billion KRW | 6.65% |
| 2011 Q1 | 21.25 Billion KRW | -4.52% |
| 2010 Q2 | 15.52 Billion KRW | -11.47% |
| 2010 FY | 22.25 Billion KRW | 31.88% |
| 2010 Q1 | 17.53 Billion KRW | 3.91% |
| 2010 Q4 | 22.25 Billion KRW | 20.1% |
| 2010 Q3 | 18.53 Billion KRW | 19.36% |
| 2009 Q2 | 19.18 Billion KRW | 1.25% |
| 2009 Q3 | 17.98 Billion KRW | -6.3% |
| 2009 Q1 | 18.95 Billion KRW | -8.84% |
| 2009 FY | 16.87 Billion KRW | -18.82% |
| 2009 Q4 | 16.87 Billion KRW | -6.14% |
| 2008 FY | 20.79 Billion KRW | 21.28% |
| 2008 Q2 | 16.02 Billion KRW | 14.91% |
| 2008 Q4 | 20.79 Billion KRW | 0.31% |
| 2008 Q3 | 20.72 Billion KRW | 29.37% |
| 2008 Q1 | 13.94 Billion KRW | -18.67% |
| 2007 Q3 | 16.03 Billion KRW | -10.97% |
| 2007 Q4 | 17.14 Billion KRW | 6.9% |
| 2007 FY | 17.14 Billion KRW | 0.0% |
| 2007 Q1 | 13.33 Billion KRW | 0.0% |
| 2007 Q2 | 18.01 Billion KRW | 35.1% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 26.365% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 72.413% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 64.338% |
| HANDOK Inc. | 94.46 Billion KRW | 65.583% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -53.045% |
| Yuhan Corporation | 284.75 Billion KRW | 88.583% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 72.048% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -99.963% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 88.743% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -0.393% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 47.328% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -66.922% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -7.368% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 32.754% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 26.365% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -4.067% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 7.576% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 32.448% |
| JW Holdings Corporation | 147.58 Billion KRW | 77.972% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 61.581% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 87.564% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 69.355% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 39.708% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -20.422% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 70.382% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 26.365% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 82.766% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 86.54% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 69.355% |
| Yuhan Corporation | 284.75 Billion KRW | 88.583% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 74.049% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 47.551% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 87.488% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 69.355% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 59.158% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 33.842% |
| CKD Bio Corp. | 69.08 Billion KRW | 52.938% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 69.06% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 54.013% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 39.858% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 39.708% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 83.307% |
| Boryung Corporation | 189.8 Billion KRW | 82.871% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 42.794% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 47.328% |
| JW Lifescience Corporation | 23.39 Billion KRW | -38.946% |